Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Llinas

Ophthalmology East Setauket, NY Medical Doctor

NPI 1194900365 CMS profile 235205

3400 Nesconset Hwy, Suite 107, East Setauket, NY 11733

Open in the dashboard

General payments

$2,763

125 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Llinas of East Setauket, NY is reported in the CMS Open Payments database as having received $2,763 across 125 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $779 33
2024 General $735 31
2023 General $498 23
2022 General $515 24
2021 General $35 2
2020 General $13 1
2019 General $190 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Llinas
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Alexander Llinas were reported at $779. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Alexander Llinas Ophthalmology median Middle half National median
2019 $190 $258 $104–$655 $163
2020 $13 $126 $45–$321 $114
2021 $35 $205 $76–$534 $132
2022 $515 $266 $100–$678 $149
2023 $498 $308 $117–$745 $160
2024 $735 $340 $127–$846 $164
2025 $779 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Oyster Point Pharma, Inc. $655 31 payments
  2. Tarsus Pharmaceuticals, Inc. $264 8 payments
  3. Bausch & Lomb Americas Inc. $237 12 payments
  4. Sun Pharmaceutical Industries Inc. $235 11 payments
  5. AbbVie, Inc. $215 11 payments
  6. Dompe US, Inc. $167 6 payments
  7. Alcon Vision LLC $155 8 payments
  8. Harrow Eye, LLC $118 6 payments
  9. New World Medical,Inc. $104 1 payment
  10. Amgen Inc. $86 5 payments
  11. Other $528 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,763 125 payments
Products named General payments · program years 2019–2025
  1. TYRVAYA Dry Eye $376 19 payments
  2. TYRVAYA Dry eyes $279 12 payments
  3. XDEMVY $264 8 payments
  4. Cequa $235 11 payments
  5. MIEBO $169 9 payments
  6. OXERVATE $167 6 payments
  7. VEVYE $118 6 payments
  8. Ahmed Glaucoma Valve $104 1 payment
  9. Streamline Surgical System $104 1 payment
  10. Kahook Dual Blade $104 1 payment
  11. Other $1,366 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 24 drugs

Part D claims

1,934

Median for Ophthalmology: 891

Drug cost

$270,563

Median for Ophthalmology: $68,233

Branded share of claims

40%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 48 $71,762
Lumigan Bimatoprost Brand 98 $60,820
Travoprost Generic 68 $22,583
Combigan Brimonidine Tartrate/Timolol Brand 43 $17,544
Simbrinza Brinzolamide/Brimonidine Tart Brand 39 $13,413
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 57 $12,613
Brinzolamide Generic 43 $11,819
Brimonidine Tartrate Generic 160 $10,307
Cyclosporine Generic 15 $9,948
Alphagan P Brimonidine Tartrate Brand 22 $7,904

The 10 drugs with the highest cost, of 24 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$245,493

Medicare's payments for the services billed

Medicare patients

1,004

Average age 76

Services billed

4,156

643 women, 361 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Ischemic heart disease 32%
Diabetes 30%
Chronic kidney disease 22%
Cancer 20%
Osteoporosis 19%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TYRVAYA
  • Oyster Point Pharma, Inc. $210
$210 — —
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $103
$103 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $85
$85 — —
VEVYE
  • Harrow Eye, LLC $76
$76 — —
MIEBO
  • Bausch & Lomb Americas Inc. $60
$60 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

125 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record